Stroke. 2002;33:831-836
doi: 10.1161/hs0302.104542
doi: 10.1161/hs0302.104542
(Stroke. 2002;33:831.)
© 2002 American Heart Association, Inc.
Original Contributions |
Involvement of Matrix Metalloproteinase in Thrombolysis-Associated Hemorrhagic Transformation After Embolic Focal Ischemia in Rats
From the Neuroprotection Research Laboratory, Departments of Neurology and Radiology, Massachusetts General Hospital, Charlestown (T.S., E.H.L.); Program in Neuroscience, Harvard Medical School, Boston, Mass (E.H.L.); and Department of Neurosurgery, Kinki University School of Medicine, Osaka-Sayama, Japan (T.S.).
Correspondence to Eng H. Lo, PhD, Neuroprotection Research Laboratory, Departments of Neurology and Radiology, Harvard Medical School, MGH East 149-2322, Charlestown, MA 02129. E-mail Lo{at}helix.mgh.harvard.edu
Background and Purpose— Thrombolytic therapy with tissue plasminogen activator (tPA) for acute ischemic stroke remains complicated by risks of hemorrhagic transformation. In this study we used a previously established quantitative rat model of tPA-associated hemorrhage to test the hypothesis that matrix metalloproteinases (MMPs) are involved.
Methods— Spontaneously hypertensive rats were subjected to embolic focal ischemia by placing homologous blood clots into the middle cerebral artery. Three groups of rats were studied: (1) untreated controls that received saline at 6 hours after ischemia; (2) rats that received tPA alone (10 mg/kg at 6 hours after ischemia); and (3) rats that received tPA plus the broad-spectrum MMP inhibitor BB-94 (50 mg/kg of BB-94 before ischemia and at 3 and 6 hours after ischemia plus tPA at 6 hours). Gelatin zymography was used to quantify MMP levels. A hemoglobin spectrophotometry method was used to quantify cerebral hemorrhage. Ischemic lesions were measured at 24 hours with tetrazolium staining.
Results— At 6, 12, and 24 hours, pro-MMP-9 and cleaved MMP-9 were upregulated in ischemic brain. At 12 hours, tPA-treated rats showed significantly higher levels of pro-MMP-9 and cleaved MMP-9 than untreated controls. By 24 hours, all rats showed evidence of hemorrhagic transformation in the ischemic territory. Rats treated with BB-94 and tPA showed significantly reduced hemorrhage volumes compared with those that received tPA alone. There was no effect on infarct size.
Conclusions— These results indicate that (1) tPA treatment increases levels of MMP-9 after embolic focal cerebral ischemia, (2) MMPs are involved in the mechanism of tPA-associated hemorrhage, and (3) combination therapies with MMP inhibitors may be useful for decreasing the risk and severity of this dreaded complication of thrombolytic therapy.
Key Words: cerebral hemorrhage • extracellular matrix • reperfusion injury • stroke • tissue plasminogen activator • rats
This article has been cited by other articles:
 |
|
 |
|
  Y. Suzuki, N. Nagai, K. Yamakawa, J. Kawakami, H. R. Lijnen, and K. Umemura Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein Blood, October 8, 2009; 114(15): 3352 - 3358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Machado, I. Y. Sazonova, A. Kozak, D. C. Wiley, A. B. El-Remessy, A. Ergul, D. C. Hess, J. L. Waller, and S. C. Fagan Minocycline and Tissue-Type Plasminogen Activator for Stroke: Assessment of Interaction Potential Stroke, September 1, 2009; 40(9): 3028 - 3033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Foerch, J. Montaner, K. L. Furie, M. M. Ning, and E. H. Lo Invited Article: Searching for oracles?: Blood biomarkers in acute stroke Neurology, August 4, 2009; 73(5): 393 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Yang, N. Nemkul, A. Shereen, A. Jone, R. S. Dunn, D. A. Lawrence, D. Lindquist, and C.-Y. Kuan Therapeutic Administration of Plasminogen Activator Inhibitor-1 Prevents Hypoxic-Ischemic Brain Injury in Newborns J. Neurosci., July 8, 2009; 29(27): 8669 - 8674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Hemmen and P. D. Lyden Multimodal Neuroprotective Therapy With Induced Hypothermia After Ischemic Stroke Stroke, March 1, 2009; 40(3_suppl_1): S126 - S128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Murata, A. Rosell, R. H. Scannevin, K. J. Rhodes, X. Wang, and E. H. Lo Extension of the Thrombolytic Time Window With Minocycline in Experimental Stroke Stroke, December 1, 2008; 39(12): 3372 - 3377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Derex and N Nighoghossian Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update J. Neurol. Neurosurg. Psychiatry, October 1, 2008; 79(10): 1093 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W. McColl, N. J. Rothwell, and S. M. Allan Systemic Inflammation Alters the Kinetics of Cerebrovascular Tight Junction Disruption after Experimental Stroke in Mice J. Neurosci., September 17, 2008; 28(38): 9451 - 9462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Cuadrado, L. Ortega, M. Hernandez-Guillamon, A. Penalba, I. Fernandez-Cadenas, A. Rosell, and J. Montaner Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release J. Leukoc. Biol., July 1, 2008; 84(1): 207 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rosell, E. Cuadrado, A. Ortega-Aznar, M. Hernandez-Guillamon, E. H. Lo, and J. Montaner MMP-9-Positive Neutrophil Infiltration Is Associated to Blood-Brain Barrier Breakdown and Basal Lamina Type IV Collagen Degradation During Hemorrhagic Transformation After Human Ischemic Stroke Stroke, April 1, 2008; 39(4): 1121 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Liu, S. Mori, H. K. Takahashi, Y. Tomono, H. Wake, T. Kanke, Y. Sato, N. Hiraga, N. Adachi, T. Yoshino, et al. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats FASEB J, December 1, 2007; 21(14): 3904 - 3916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Z. Lee, Z. Xue, Y. Zhu, G.-Y. Yang, and W. L. Young Matrix Metalloproteinase-9 Inhibition Attenuates Vascular Endothelial Growth Factor-Induced Intracerebral Hemorrhage Stroke, September 1, 2007; 38(9): 2563 - 2568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-Q. Zhao, E. Tejima, and E. H. Lo Neurovascular Proteases in Brain Injury, Hemorrhage and Remodeling After Stroke Stroke, February 1, 2007; 38(2): 748 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Hemmen and P. D. Lyden Induced Hypothermia for Acute Stroke Stroke, February 1, 2007; 38(2): 794 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Carrera, P. Michel, P. -A. Despland, M. Maeder-Ingvar, C. Ruffieux, D. Debatisse, J. Ghika, G. Devuyst, and J. Bogousslavsky Continuous assessment of electrical epileptic activity in acute stroke. Neurology, July 11, 2006; 67(1): 99 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wang, S.-R. Lee, S.-Z. Guo, W. J. Kim, J. Montaner, X. Wang, and E. H. Lo Reduction of Tissue Plasminogen Activator-Induced Matrix Metalloproteinase-9 by Simvastatin in Astrocytes Stroke, July 1, 2006; 37(7): 1910 - 1912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ning, K. L. Furie, W. J. Koroshetz, H. Lee, M. Barron, M. Lederer, X. Wang, M. Zhu, A. G. Sorensen, E. H. Lo, et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke Neurology, May 23, 2006; 66(10): 1550 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-R. Lee, H.-Y. Kim, J. Rogowska, B.-Q. Zhao, P. Bhide, J. M. Parent, and E. H. Lo Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J. Neurosci., March 29, 2006; 26(13): 3491 - 3495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tsuji, T. Aoki, E. Tejima, K. Arai, S.-R. Lee, D. N. Atochin, P. L. Huang, X. Wang, J. Montaner, and E. H. Lo Tissue Plasminogen Activator Promotes Matrix Metalloproteinase-9 Upregulation After Focal Cerebral Ischemia Stroke, September 1, 2005; 36(9): 1954 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Benchenane, V. Berezowski, C. Ali, M. Fernandez-Monreal, J. P. Lopez-Atalaya, J. Brillault, J. Chuquet, A. Nouvelot, E. T. MacKenzie, G. Bu, et al. Tissue-Type Plasminogen Activator Crosses the Intact Blood-Brain Barrier by Low-Density Lipoprotein Receptor-Related Protein-Mediated Transcytosis Circulation, May 3, 2005; 111(17): 2241 - 2249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Alsop, E. Makovetskaya, S. Kumar, M. Selim, and G. Schlaug Markedly Reduced Apparent Blood Volume on Bolus Contrast Magnetic Resonance Imaging as a Predictor of Hemorrhage After Thrombolytic Therapy for Acute Ischemic Stroke Stroke, April 1, 2005; 36(4): 746 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, Z. G. Zhang, C. Zhang, R. L. Zhang, and M. Chopp Intravenous Administration of a GPIIb/IIIa Receptor Antagonist Extends the Therapeutic Window of Intra-Arterial Tenecteplase-Tissue Plasminogen Activator in a Rat Stroke Model Stroke, December 1, 2004; 35(12): 2890 - 2895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, K. Tsuji, S.-R. Lee, M. Ning, K. L. Furie, A. M. Buchan, and E. H. Lo Mechanisms of Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke Stroke, November 1, 2004; 35(11_suppl_1): 2726 - 2730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Castellanos, R. Leira, J. Serena, M. Blanco, S. Pedraza, J. Castillo, and A. Davalos Plasma Cellular-Fibronectin Concentration Predicts Hemorrhagic Transformation After Thrombolytic Therapy in Acute Ischemic Stroke Stroke, July 1, 2004; 35(7): 1671 - 1676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dittmar, G. Kiourkenidis, M. Horn, S. Bollwein, G. Bernhardt, G. A. Rosenberg, and T. Pfefferkorn Cerebral Ischemia, Matrix Metalloproteinases, and TNF-{alpha}: MMP Inhibitors May Act Not Exclusively by Reducing MMP Activity * Response Stroke, July 1, 2004; 35(7): e338 - e340. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Maier, L. Hsieh, F. Yu, P. Bracci, and P. H. Chan Matrix Metalloproteinase-9 and Myeloperoxidase Expression: Quantitative Analysis by Antigen Immunohistochemistry in a Model of Transient Focal Cerebral Ischemia Stroke, May 1, 2004; 35(5): 1169 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-Q. Zhao, Y. Ikeda, H. Ihara, T. Urano, W. Fan, S. Mikawa, Y. Suzuki, K. Kondo, K. Sato, N. Nagai, et al. Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice Blood, April 1, 2004; 103(7): 2610 - 2616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Danton and W. D. Dietrich The Search for Neuroprotective Strategies in Stroke AJNR Am. J. Neuroradiol., February 1, 2004; 25(2): 181 - 194. [Full Text] [PDF]
|
|
|
|
|
|
E. H. Lo, J. P. Broderick, and M. A. Moskowitz tPA and Proteolysis in the Neurovascular Unit Stroke, February 1, 2004; 35(2): 354 - 356. [Full Text] [PDF]
|
|
|
|
|
|
J. Montaner, I. Fernandez-Cadenas, C. A. Molina, J. Monasterio, J. F. Arenillas, M. Ribo, M. Quintana, P. Chacon, A. L. Andreu, and J. Alvarez-Sabin Safety Profile of Tissue Plasminogen Activator Treatment Among Stroke Patients Carrying a Common Polymorphism (C-1562T) in the Promoter Region of the Matrix Metalloproteinase-9 Gene Stroke, December 1, 2003; 34(12): 2851 - 2855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gautier, O. Petrault, P. Gele, M. Laprais, M. Bastide, A. Bauters, D. Deplanque, B. Jude, J. Caron, and R. Bordet Involvement of Thrombolysis in Recombinant Tissue Plasminogen Activator-Induced Cerebral Hemorrhages and Effect on Infarct Volume and Postischemic Endothelial Function Stroke, December 1, 2003; 34(12): 2975 - 2979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Pfefferkorn and G. A. Rosenberg Closure of the Blood-Brain Barrier by Matrix Metalloproteinase Inhibition Reduces rtPA-Mediated Mortality in Cerebral Ischemia With Delayed Reperfusion Stroke, August 1, 2003; 34(8): 2025 - 2030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, Z. G. Zhang, R. Zhang, D. Morris, M. Lu, B. S. Coller, and M. Chopp Adjuvant Treatment With a Glycoprotein IIb/IIIa Receptor Inhibitor Increases the Therapeutic Window for Low-Dose Tissue Plasminogen Activator Administration in a Rat Model of Embolic Stroke Circulation, June 10, 2003; 107(22): 2837 - 2843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Vo, F. Santiago, W. Lin, C. Y. Hsu, Y. Lee, and J.-M. Lee MR Imaging Enhancement Patterns as Predictors of Hemorrhagic Transformation in Acute Ischemic Stroke AJNR Am. J. Neuroradiol., April 1, 2003; 24(4): 674 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Montaner, C. A. Molina, J. Monasterio, S. Abilleira, J. F. Arenillas, M. Ribo, M. Quintana;, and J. Alvarez-Sabin Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke Circulation, February 4, 2003; 107(4): 598 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Castellanos, R. Leira, J. Serena, J. M. Pumar, I. Lizasoain, J. Castillo, A. Davalos, and G. F. Hamann Plasma Metalloproteinase-9 Concentration Predicts Hemorrhagic Transformation in Acute Ischemic Stroke * Editorial Comment Stroke, January 1, 2003; 34(1): 40 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Aoki, T. Sumii, T. Mori, X. Wang, and E. H. Lo Blood-Brain Barrier Disruption and Matrix Metalloproteinase-9 Expression During Reperfusion Injury: Mechanical Versus Embolic Focal Ischemia in Spontaneously Hypertensive Rats Stroke, November 1, 2002; 33(11): 2711 - 2717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Dijkhuizen, M. Asahi, O. Wu, B. R. Rosen, and E. H. Lo Rapid Breakdown of Microvascular Barriers and Subsequent Hemorrhagic Transformation After Delayed Recombinant Tissue Plasminogen Activator Treatment in a Rat Embolic Stroke Model Stroke, August 1, 2002; 33(8): 2100 - 2104. [Abstract] [Full Text] [PDF]
|
|